ClinicalTrials.gg
TerminatedNCT02150967Updated Jul 3, 2023Results posted

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

A Phase 2 interventional study of BGJ398 (infigratinib) in Advanced Cholangiocarcinoma and FGFR2 Gene Mutation, sponsored by QED Therapeutics, Inc.. Terminated at 37 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by QED Therapeutics, Inc. (part of BridgeBio) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated early due to limited efficacy in Cohorts 2 and 3 (exploratory endpoints). Termination was not due to concerns about safety and had no impact on the primary efficacy analysis (ie, results reported for Cohort 1).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 111 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Enrollment
59th of 279
143 · median 44
Started
2014
with 17 others
Phase 2
94 of 328
20 open now
Registered
64th of 328
by date

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 59th largest by enrollment of the 279 interventional ones that give a count, is one of 18 that started in 2014, is one of 94 in phase 2, and was the 64th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 287 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic alterations.

Read the detailed description

Adult patients with histologically or cytologically confirmed advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or translocations or other FGFR genetic alterations have been enrolled. Subjects must have received at least one prior regimen containing gemcitabine with or without cisplatin for advanced/metastatic disease. Subjects should have had evidence of progressive disease following their prior regimen or if prior treatment was discontinued due to toxicity must have continued evidence of measurable disease. Up to approximately 160 adult patients over age 18, both male and female were planned for enrollment.

Three cohorts of subjects comprise the study population:

Cohort 1: subjects with FGFR2 gene fusions (ie, fusions or rearrangements [formerly translocations]).

Cohort 2: subjects with FGFR genetic alterations other than FGFR2 gene fusions or rearrangements.

Cohort 3: subjects with FGFR2 gene fusions or rearrangements who have received a prior FGFR inhibitor.

All subjects received oral BGJ398 (infigratinib), once-daily, on a three weeks on (21 days), one week off (7 days) schedule. One treatment cycle consists of 28 days.

Notes:

Cohort 1 was pre-specified as the primary analysis population. Results of these analyses were previously disclosed (posted 22 June 2022). There were no additional efficacy or safety endpoints to assess in Cohort 1 after primary completion (01 March 2021).

Cohorts 2 and 3 were added at protocol amendment (PA) 4 to support only exploratory efficacy objectives of the study. These cohorts were ongoing the time of primary completion (01 March 2021). After interim review of the data from these cohorts (as permitted by the protocol) only limited efficacy was observed and the sponsor terminated the study early. Therefore, a formal efficacy analysis was not performed for Cohorts 2 and 3. However, baseline characteristics and safety data were analyzed.

03

Conditions studied

  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Mutation

Browse trials for

Keywords

  • cholangiocarcinoma,
  • FGFR2 gene fusion,
  • FGFR genetic alteration
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with or cytologically confirmed cholangiocarcinoma at the time of diagnosis.

Patients with cancers of the gallbladder or ampulla of Vater are not eligible.

  • Patients must have received at least one prior regimen containing gemcitabine with or without cisplatin for advanced/ disease. Patient should have evidence of progressive disease following prior regimen, or if prior treatment discontinued due to toxicity must have continued evidence of measurable or evaluable disease.

Exclusion criteria

Exclusion criteria:

  • Prior or current treatment with a MEK inhibitor (all Cohorts), BGJ398 (infigratinib) (all Cohorts), or selective FGFR inhibitor (Cohorts 1 and 2 only).
  • insufficient organ function

    • (ANC) \< 1,000/mm3 [1.0 x 10\^9/L]
    • \< 75,000/mm3 [75 x 10\^9/L]
    • \< 109.0 g/dL
    • Total > 1.5x (ULN)
    • /glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/glutamic pyruvic transaminase (ALT/SGPT) > 2.5x ULN (AST and ALT > 5x ULN in the presence of liver )
    • Serum creatinine > 1.5x ULN and a calculated or measured \< 45 mL/min
    • Inorganic phosphorus outside of normal limits
    • Total and ionized serum calcium outside of normal limits

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    BGJ398 (infigratinib)

    To estimate the anti-tumor activity of BGJ398 (infigratinib)

    Drug: BGJ398 (infigratinib)

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) as Assessed by Blinded Independent Central Imaging Review (BICR)

    ORR is defined as the percentage (%) of subjects with a best overall response of Complete Response (CR) or Partial Response (PR), as per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions). Results were previously disclosed (22 June 2022). There are no additional efficacy endpoints to assess for Cohort 1, thus efficacy data were not re-analyzed for the final analysis. Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

    Time frame: Analysis was conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.

Secondary outcomes

  1. Overall Response Rate (ORR) as Assessed by the Investigator

    ORR is defined as the percentage (%) of subjects with a best overall response of CR or PR, evaluated by CT or MRI scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) only. These results were previously disclosed (22 June 2022). There are no additional efficacy endpoints to assess for Cohort 1, thus efficacy data were not re-analyzed for the final analysis. Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

    Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff for the primary analysis was 01 March 2021.

  2. Best Overall Response (BOR)

    BOR is defined as the best overall response a subject achieved during the study before any subsequent antineoplastic therapy. The endpoint is summarized for the rate of BOR of CR, PR, progressive disease (PD), and stable disease (SD), evaluated by CT or MRI scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. PD: at least a 20% increase in the sum of diameters of all target lesions from that of the smallest sum on study and an absolute increase in target lesion of at least 5mm. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusion)

    Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.

  3. Disease Control Rate (DCR)

    DCR is the percentage (%) of subjects with a BOR of CR, PR, or SD, evaluated by CT or MRI scans every 28 days. Results are based on both BICR and on Investigator assessment. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). There are no additional efficacy endpoints to assess for Cohort 1, thus efficacy data were not re-analyzed for the final analysis. Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

    Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.

  4. Progression-Free Survival (PFS)

    PFS was calculated as the number of months from the first dose of study drug to the first documented progression or death due to any cause, whichever occurred earlier. Subjects without an assessment of progression or death were censored at the last adequate tumor assessment. For subjects who had an event after ≥2 missed visits, the subject was censored at the last adequate tumor assessment before the missing visit. Disease progression was assessed per RECIST (v1.1) and defined as at least a 20% increase in the sum of diameters of all target lesions from that of the smallest sum on study and an absolute increase in target lesion of at least 5mm. Results are based on both BICR and on Investigator assessment. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

    Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.

  5. Overall Survival (OS)

    OS was defined as the time (months) from the date of start of treatment to the date of death due to any cause. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

    Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.

  6. Duration of Response (DOR)

    DOR is defined as the time (months) from the initial response to the time of the event; defined as the first documented progression or death due to any cause, whichever was earlier. Note that results are based on a subgroup of subjects with confirmed responses (CR or PR) as assessed by BICR or by the Investigator. RECIST (v1.1) response criteria was as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

    Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.

  7. Response Onset

    Response onset was defined as the time (months) from the first study treatment administration date to the initial response. Note that results are based on a subgroup of subjects with confirmed responses (CR or PR) as assessed by BICR or by the Investigator. RECIST (v1.1) response criteria was as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

    Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.

Other outcomes

  1. Growth Modulation Index (GMI)

    The GMI is defined as the ratio of PFS (months) during treatment with infigratinib relative to the time (months) to progression (TTP) during treatment with last prior line of therapy. Subjects served as their own control. Results are provided for both BICR and Investigator assessment. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

    Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.

07

Results

Posted Jul 15, 2022

Participant flow

Participants with a diagnosis of advanced or metastatic cholangiocarcinoma were recruited to this open-label, single-arm global study across 20 centers (9 in the US, 5 in W. Europe, 6 in Asia) based on documented evidence of FGFR gene alteration. The first participant was treated on 23 July 2014. The data cutoff for the primary analysis (Cohort 1 only) was 01 March 2021.The data cutoff for the final analysis (Cohort 2 and 3 only) was 07 February 2022.

Participant flow — Overall Study
MilestoneCohort 1: FGFR2 FusionsCohort 2: Other FGFR AlterationsCohort 3: FGFR2 Fusions and Prior FGFR Inhibitor
Started1082510
Treatment ongoing000
Treatment ended1082510
Completed1082510
Not completed000

Outcome measures

PrimaryOverall Response Rate (ORR) as Assessed by Blinded Independent Central Imaging Review (BICR)

ORR is defined as the percentage (%) of subjects with a best overall response of Complete Response (CR) or Partial Response (PR), as per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions). Results were previously disclosed (22 June 2022). There are no additional efficacy endpoints to assess for Cohort 1, thus efficacy data were not re-analyzed for the final analysis. Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

Time frame:
Analysis was conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Reported as:
Number · Percentage (%) of subjects with CR or PR
Overall Response Rate (ORR) as Assessed by Blinded Independent Central Imaging Review (BICR)
Percentage (%) of subjects with CR or PRCohort 1: FGFR2 Fusions
Overall Response Rate (ORR) as Assessed by Blinded Independent Central Imaging Review (BICR)23.1 (15.6 to 32.2)
SecondaryOverall Response Rate (ORR) as Assessed by the Investigator

ORR is defined as the percentage (%) of subjects with a best overall response of CR or PR, evaluated by CT or MRI scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) only. These results were previously disclosed (22 June 2022). There are no additional efficacy endpoints to assess for Cohort 1, thus efficacy data were not re-analyzed for the final analysis. Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

Time frame:
Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff for the primary analysis was 01 March 2021.
Reported as:
Number · Percentage (%) of subjects with CR or PR
Overall Response Rate (ORR) as Assessed by the Investigator
Percentage (%) of subjects with CR or PRCohort 1: FGFR2 Fusion/Rearrangements
Overall Response Rate (ORR) as Assessed by the Investigator32.4 (23.7 to 42.1)
SecondaryBest Overall Response (BOR)

BOR is defined as the best overall response a subject achieved during the study before any subsequent antineoplastic therapy. The endpoint is summarized for the rate of BOR of CR, PR, progressive disease (PD), and stable disease (SD), evaluated by CT or MRI scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. PD: at least a 20% increase in the sum of diameters of all target lesions from that of the smallest sum on study and an absolute increase in target lesion of at least 5mm. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusion)

Time frame:
Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Reported as:
Count of participants · Participants
Best Overall Response (BOR)
ParticipantsCohort 1: FGFR2 Fusion/Rearrangements
BOR by BICR — Confirmed CR1
BOR by BICR — Confirmed PR24
BOR by BICR — Stable Disease66
BOR by BICR — Progressive Disease11
BOR by BICR — Not Done6
BOR by Investigator — Confirmed CR0
BOR by Investigator — Confirmed PR35
BOR by Investigator — Stable Disease56
BOR by Investigator — Progressive Disease11
BOR by Investigator — Not Done6
SecondaryDisease Control Rate (DCR)

DCR is the percentage (%) of subjects with a BOR of CR, PR, or SD, evaluated by CT or MRI scans every 28 days. Results are based on both BICR and on Investigator assessment. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). There are no additional efficacy endpoints to assess for Cohort 1, thus efficacy data were not re-analyzed for the final analysis. Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

Time frame:
Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Reported as:
Number · Percentage (%) with CR, PR, or SD
Disease Control Rate (DCR)
Percentage (%) with CR, PR, or SDCohort 1: FGFR2 Fusion/Rearrangements
DCR by BICR84.3 (76.0 to 90.6)
DCR by Investigator84.3 (76.0 to 90.6)
SecondaryProgression-Free Survival (PFS)

PFS was calculated as the number of months from the first dose of study drug to the first documented progression or death due to any cause, whichever occurred earlier. Subjects without an assessment of progression or death were censored at the last adequate tumor assessment. For subjects who had an event after ≥2 missed visits, the subject was censored at the last adequate tumor assessment before the missing visit. Disease progression was assessed per RECIST (v1.1) and defined as at least a 20% increase in the sum of diameters of all target lesions from that of the smallest sum on study and an absolute increase in target lesion of at least 5mm. Results are based on both BICR and on Investigator assessment. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

Time frame:
Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsCohort 1: FGFR2 Fusion/Rearrangements
PFS by BICR7.29 (5.59 to 7.56)
PFS by Investigator6.74 (5.55 to 7.56)
SecondaryOverall Survival (OS)

OS was defined as the time (months) from the date of start of treatment to the date of death due to any cause. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

Time frame:
Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Reported as:
Median · months
Overall Survival (OS)
monthsCohort 1: FGFR2 Fusion/Rearrangements
Overall Survival (OS)11.86 (10.68 to 14.85)
SecondaryDuration of Response (DOR)

DOR is defined as the time (months) from the initial response to the time of the event; defined as the first documented progression or death due to any cause, whichever was earlier. Note that results are based on a subgroup of subjects with confirmed responses (CR or PR) as assessed by BICR or by the Investigator. RECIST (v1.1) response criteria was as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

Time frame:
Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Reported as:
Median · months
Duration of Response (DOR)
monthsCohort 1: FGFR2 Fusion/Rearrangements
DOR by BICR5.55 (3.78 to 7.66)
DOR by Investigator7.23 (5.16 to 9.00)
SecondaryResponse Onset

Response onset was defined as the time (months) from the first study treatment administration date to the initial response. Note that results are based on a subgroup of subjects with confirmed responses (CR or PR) as assessed by BICR or by the Investigator. RECIST (v1.1) response criteria was as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

Time frame:
Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Reported as:
Median · months
Response Onset
monthsCohort 1: FGFR2 Fusion/Rearrangements
Response onset by BICR3.61 (1.38 to 7.36)
Response onset by Investigator1.94 (1.38 to 18.76)
Other pre-specifiedGrowth Modulation Index (GMI)

The GMI is defined as the ratio of PFS (months) during treatment with infigratinib relative to the time (months) to progression (TTP) during treatment with last prior line of therapy. Subjects served as their own control. Results are provided for both BICR and Investigator assessment. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

Time frame:
Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Reported as:
Median · Ratio (PFS/TTP) in Months
Growth Modulation Index (GMI)
Ratio (PFS/TTP) in MonthsCohort 1: FGFR2 Fusion/Rearrangements
PFS by BICR1.22 (0.00 to 120)
PFS by Investigator1.24 (0.00 to 120)
Post-hocRetrospective Analysis of Post-second-line Antineoplastic Treatment Outcomes on ORR

Post-hoc subgroup assessment of efficacy in those subjects who were receiving infigratinib as a third or later line of treatment. Investigator-assessed ORR was obtained from subjects' medical histories to provide a baseline evaluation of their response after historical second-line antineoplastic treatment prior to infigratinib treatment. Investigator-assessed ORR was then calculated in the same subjects after third- or later-line infigratinib therapy. ORR is defined as the percentage (%) of patients with CR or PR, per RECIST (v1.1). RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (22 June 2022). No formal efficacy analyses were performed for Cohorts 2 and 3.

Time frame:
Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Reported as:
Number · Percentage (%) of patients with CR or PR
Retrospective Analysis of Post-second-line Antineoplastic Treatment Outcomes on ORR
Percentage (%) of patients with CR or PRCohort 1: FGFR2 Fusion/Rearrangements
After Second-Line Therapy (Prior to Infigratinib Treatment)0 (0.0 to 6.1)
Third or Later-Line Therapy (Infigratinib)28.8 (17.8 to 42.1)
Post-hocRetrospective Analysis of Post-second-line Antineoplastic Treatment Outcomes on PFS

Post-hoc subgroup assessment of efficacy in those subjects who were receiving infigratinib as a third or later line of treatment. Investigator-assessed PFS was obtained from subjects' medical histories to provide a baseline evaluation of their response after historical second-line antineoplastic treatment prior to infigratinib treatment. Investigator-assessed PFS was then calculated in the same subjects after third- or later-line infigratinib therapy. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

Time frame:
Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Reported as:
Median · months
Retrospective Analysis of Post-second-line Antineoplastic Treatment Outcomes on PFS
monthsCohort 1: FGFR2 Fusion/Rearrangements
After Second-Line Therapy (Prior to Infigratinib Treatment)5.36 (3.25 to 8.15)
Third or Later-Line Therapy (Infigratinib)6.93 (4.76 to 7.59)
Post-hocRetrospective Analysis of Post-second-line Antineoplastic Treatment Outcomes on BOR

Post-hoc subgroup assessment of efficacy in those subjects who were receiving infigratinib as a third or later line of treatment. Investigator-assessed BOR was obtained from subjects' medical histories to provide a baseline evaluation of their response after historical second-line antineoplastic treatment prior to infigratinib treatment. Investigator-assessed BOR was then calculated in the same subjects after third- or later-line infigratinib therapy. The endpoint is summarized for the rate of BOR of PD, SD, PR, and CR. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.

Time frame:
Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Reported as:
Count of participants · Participants
Retrospective Analysis of Post-second-line Antineoplastic Treatment Outcomes on BOR
ParticipantsCohort 1: FGFR2 Fusion/Rearrangements
After Second-Line Therapy (Prior to Infigratinib Treatment) — Complete response0
After Second-Line Therapy (Prior to Infigratinib Treatment) — Partial response0
After Second-Line Therapy (Prior to Infigratinib Treatment) — Stable disease19
After Second-Line Therapy (Prior to Infigratinib Treatment) — Progressive disease22
After Second-Line Therapy (Prior to Infigratinib Treatment) — Unknown18
After Second-Line Therapy (Prior to Infigratinib Treatment) — Not done0
Third or Later-Line Therapy (Infigratinib) — Complete response0
Third or Later-Line Therapy (Infigratinib) — Partial response17
Third or Later-Line Therapy (Infigratinib) — Stable disease31
Third or Later-Line Therapy (Infigratinib) — Progressive disease7
Third or Later-Line Therapy (Infigratinib) — Unknown0
Third or Later-Line Therapy (Infigratinib) — Not done4

Adverse events

Collected over From first administration of infigratinib with follow-up of at least 10 months after initial exposure. Data cutoff for Cohort 1 (primary analysis population) was 01 March 2021 (disclosed 22 June 2022). Data cutoff for Cohorts 2 and 3 (exploratory analysis only) was 07 February 2022.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: FGFR2 Fusions93/108 (86.1%)35/108 (32.4%)107/108 (99.1%)
Cohort 2: Other FGFR Genetic Alterations19/25 (76%)11/25 (44%)25/25 (100%)
Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor7/10 (70%)2/10 (20%)10/10 (100%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventCohort 1: FGFR2 FusionsCohort 2: Other FGFR Genetic AlterationsCohort 3: FGFR2 Fusions and Prior FGFR Inhibitor
AscitesGastrointestinal disorders2/1080/251/10
HypophosphataemiaMetabolism and nutrition disorders2/1080/251/10
NauseaGastrointestinal disorders0/1080/251/10
VomitingGastrointestinal disorders0/1080/251/10
Gastrooesophageal reflux diseaseGastrointestinal disorders0/1080/251/10
PyrexiaGeneral disorders4/1082/250/10
Abdominal painGastrointestinal disorders2/1081/250/10
Gastrointestinal haemorrhageGastrointestinal disorders1/1081/250/10
Intestinal ischaemiaGastrointestinal disorders0/1081/250/10
General physical health deteriorationGeneral disorders1/1081/250/10
Most frequent other events
Showing 10 of 119
Most frequent other events
EventCohort 1: FGFR2 FusionsCohort 2: Other FGFR Genetic AlterationsCohort 3: FGFR2 Fusions and Prior FGFR Inhibitor
HyperphosphataemiaMetabolism and nutrition disorders83/10823/257/10
StomatitisGastrointestinal disorders59/10813/257/10
EpistaxisRespiratory, thoracic and mediastinal disorders19/1085/256/10
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders37/1086/255/10
ConstipationGastrointestinal disorders34/10811/253/10
FatigueGeneral disorders44/10810/253/10
Dry eyeEye disorders39/1083/254/10
NauseaGastrointestinal disorders21/10810/253/10
AlopeciaSkin and subcutaneous tissue disorders43/1089/251/10
ArthralgiaMusculoskeletal and connective tissue disorders35/1084/251/10

Baseline characteristics

Full Analysis Set (FAS), defined as all subjects who had received at least 1 dose of infigratinib.

Age, Categorical
Age, Categorical(Participants)Cohort 1: FGFR2 FusionsCohort 2: Other FGFR Genetic AlterationsCohort 3: FGFR2 Fusions and Prior FGFR InhibitorTotal
<=18 years0000
Between 18 and 65 years82178107
>=65 years268236
Age, Continuous
Age, Continuous(years)Cohort 1: FGFR2 FusionsCohort 2: Other FGFR Genetic AlterationsCohort 3: FGFR2 Fusions and Prior FGFR InhibitorTotal
Mean53.4 ± 13.0859.9 ± 9.8951.8 ± 12.0754.0 ± 12.88
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: FGFR2 FusionsCohort 2: Other FGFR Genetic AlterationsCohort 3: FGFR2 Fusions and Prior FGFR InhibitorTotal
Female6712382
Male4113761
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: FGFR2 FusionsCohort 2: Other FGFR Genetic AlterationsCohort 3: FGFR2 Fusions and Prior FGFR InhibitorTotal
American Indian or Alaska Native0000
Asian112013
Native Hawaiian or Other Pacific Islander0000
Black or African American4127
White78228108
More than one race0000
Unknown or Not Reported150015
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: FGFR2 FusionsCohort 2: Other FGFR Genetic AlterationsCohort 3: FGFR2 Fusions and Prior FGFR InhibitorTotal
North America7712594
Europe2411540
South Korea0101
Singapore4004
Taiwan1001
Thailand2103
ECOG PS
ECOG PS(Participants)Cohort 1: FGFR2 FusionsCohort 2: Other FGFR Genetic AlterationsCohort 3: FGFR2 Fusions and Prior FGFR InhibitorTotal
04511359
16213782
21102
Primary site of cancer
Primary site of cancer(Participants)Cohort 1: FGFR2 FusionsCohort 2: Other FGFR Genetic AlterationsCohort 3: FGFR2 Fusions and Prior FGFR InhibitorTotal
Bile Duct1052410139
Cholangiocarcinoma1102
Liver2002
Non-Liver Metastatic Site
Non-Liver Metastatic Site(Participants)Cohort 1: FGFR2 FusionsCohort 2: Other FGFR Genetic AlterationsCohort 3: FGFR2 Fusions and Prior FGFR InhibitorTotal
No metastatic site5409
Had metastatic site1022110133
Missing1001

5 further baseline measures are reported on the registry.

08

Study locations

37 sites
  • QED Investigative Site
    Phoenix, Arizona 85054, United States
  • QED Investigative Site
    Los Angeles, California 90033, United States
  • QED Investigative Site
    Los Angeles, California 90095, United States
  • QED Investigative Site
    San Francisco, California 94158, United States
  • QED Investigative Site
    Boston, Massachusetts 02114, United States
  • QED Investigative Site
    Detroit, Michigan 48201, United States
  • QED Investigative Site
    New York, New York 10016, United States
  • QED Investigative Site
    New York, New York 10029, United States
  • QED Investigative Site
    New York, New York 10065, United States
  • QED Investigative Site
    Columbus, Ohio 43221, United States
  • QED Investigative Site
    Houston, Texas 77030-4009, United States
  • QED Investigative Site
    Brussels, 1200, Belgium
  • QED Investigative Site
    Leuven, 3000, Belgium
  • QED Investigative Site
    Koeln, Nordrhein-Westfalen 50937, Germany
  • QED Investigative Site
    Heidelberg, 69120, Germany
  • QED Investigative Site
    Tuebingen, Germany
  • QED Investigative Site
    Ancona, AN 60126, Italy
  • QED Investigative Site
    Milano, MI 20132, Italy
  • QED Investigative Site
    Roma, RM 00168, Italy
  • QED Investigative Site
    Seoul, Korea 03080, Korea, Republic of
  • QED Investigative Site
    Seoul, Korea 06351, Korea, Republic of
  • QED Investigative Site
    Moscow, 125367, Russian Federation
  • QED Investigative Site
    Volzhskiy, 404133, Russian Federation
  • QED Investigative Site
    Singapore, 119228, Singapore
  • QED Investigative Site
    Singapore, 169610, Singapore
  • QED Investigative Site
    Barcelona, 8035, Spain
  • QED Investigative Site
    Barcelona, 8908, Spain
  • QED Investigative Site
    Madrid, 28050, Spain
  • QED Investigative Site
    Taipei, Taiwan ROC 10041, Taiwan
  • QED Investigative Site
    Zhunan, 35053, Taiwan
  • QED Investigative Site
    Khon Kaen, THA 40002, Thailand
  • QED Investigative Site
    Bangkok, 10330, Thailand
  • QED Investigative Site
    Bangkok, 10400, Thailand
  • QED Investigative Site
    Bebington, CH63 4JY, United Kingdom
  • QED Investigative Site
    Birmingham, B15 2TH, United Kingdom
  • QED Investigative Site
    Manchester, M20 4BX, United Kingdom
  • QED Investigative Site
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Publications

  • Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):803-815. doi: 10.1016/S2468-1253(21)00196-5. Epub 2021 Aug 3. PubMed 34358484 ↗
  • Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28. PubMed 29182496 ↗
  • Borad MJ, Gores GJ, Roberts LR. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. Curr Opin Gastroenterol. 2015 May;31(3):264-8. doi: 10.1097/MOG.0000000000000171. PubMed 25763789 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in Mar 2021, 79 months.

Results were first posted in Jul 2022, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2014
First posted
May 30, 2014
StartActual
Jul 23, 2014
Primary completionActual
Mar 1, 2021
CompletionActual
Feb 7, 2022
Results first posted
Jul 15, 2022
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02150967
Responsible party
Sponsor
First posted
May 30, 2014
Start date
Jul 23, 2014
Primary completion
Mar 1, 2021
Completion
Feb 7, 2022
Results posted
Jul 15, 2022
Last update
Jul 3, 2023

Study contacts

QED Therapeutics
study director · QED Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infigratinib

Start the discussion